The enclosed peer-reviewed journal article is provided in the interest of free exchange of truthful scientific information. Restore ® wound care dressings* are intended for single use in the management of partial-and full-thickness wounds.
L eg ulcers have substantial medical consequences and considerable psychosocial repercussions. Venous leg ulcers and mixed leg ulcers predominantly of venous origin require a therapeutic approach that is based on two complementary methods: the application of the aetiological treatment, an effective venous compression, thereby treating the factor that triggers the ulceration, and local care by means of a suitable primary dressing placed in contact with the lesion and with surrounding skin (Philips et al, 2000) .
Since the 1980s, the conventional greasy, non-absorbent wound dressings have been joined by modern dressings that constitute a veritable therapeutic alternative for the local management of chronic wounds. These include the hydrocolloids (adhesive dressings based on carboxymethylcellulose) which, in randomized clinical trials, have clearly demonstrated their advantages in the healing of chronic wounds (Friedman and Daniel, 1984; Gorse and Messner; 1987; Alm et al, 1989; Brandrup et al, 1990) , under the concept of 'healing in a moist environment', as described in 1962 by Winter (1962 Winter ( , 1963 .
Still more recently, and in a move to improve patient comfort (reduced dressing change frequency), dressings with a high-absorptive capacity, hydrocellular dressings, were developed and made available to the medical and paramedical staff (Pessenhofer, 1992; Zuccarelli, 1992; Bowszyc et al, 1995; Bale et al, 1997) .
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Urgocell Non-Adhesive (NA), composed of a very absorbent expanded alveolar polyurethane foam and a useful surface area of 100%, meaning that it may be cut according to the wound surface. The wound and peri-lesional skin are covered by an Urgotul dressing which has been widely recognized as efficient in the healing process of chronic and acute wounds Letouze et al, 2004; Smith et al, 2004 ). A clinical trial was then conducted to observe the performance (efficacy, tolerance and acceptability) of this new wound dressing in the treatment of venous or mixed leg ulcers.
Materials and methods
This was a phase III, multicentre clinical trial conducted in 15 investigating centres that included hospital dermatology and vascular medicine departments and private practice dermatologists and phlebologists. This non-comparative trial was prospective and included 43 patients (outpatients or patients initially hospitalized then discharged) presenting with venous or mixed leg ulcers (ankle brachial pressure index (ABPI) not less than 0.8) and treated for 6 weeks maximum. The study ulcer was to be between 3 cm 2 and 50 cm 2 in size and was not to have been present for more than 18 months. Clinically infected or cancerous ulcers were not to be included in this clinical trial.
The aetiology of the ulcers treated in this study was based on physical examination and on patient medical history which, in the vast majority of cases, was already well known and documented. It was not, therefore, considered necessary to perform a Doppler ultrasound systematically at the start of the trial.
Ethics
Ethical approval was obtained from the Lorraine Medical Ethics Committee in France. The study was conducted according to European regulations under 'good clinical practice'. All subjects received detailed information on the study's conduct and gave written consent.
Trial treatment
The Urgocell NA dressing (Cellosorb NA Laboratoires Urgo, Chenôve, France) is an absorbent, non-adhesive, non-occlusive dressing developed from lipid-colloid technology (TLC). It comprises three layers: a non-adherent, lipid-colloid interface (an Urgotul dressing in contact with the wound and peri-lesional skin), an intermediate layer composed of highly-absorbent polyurethane foam, and an outer layer made up of a non-woven, non-occlusive polyurethane support. Local cleansing operations were conducted exclusively with saline solution. The dressing was then applied directly to the wound bed and fixed by a support bandage. The study dressing may be cut, if necessary, as its whole surface is absorbent. The frequency with which the dressing has to be changed is dependent on wound condition and the volume of exudate. The investigators were asked to associate the tested dressing by static or removable compression, i.e. aetiological treatment essential for the management of such trophic disorders. However, while compression therapy was imposed by study protocol, its nature, i.e. using monolayer or multilayer, was left to the investigator's convenience, owing to the fact the study involved different physicians.
Endpoints
The main endpoint was the reduction in wound surface area after 6 weeks of treatment by the Urgocell NA dressing. This was calculated from wound tracings made weekly (under a standardized procedure provided by the sponsor at the start of the trial). In addition to these tracings, the investigator also performed physical examinations and took photographs throughout the entire follow-up period. Secondary endpoints included tolerance, which was evaluated by the investigating physician during the weekly visits (occurrence of local adverse events).
The dressing acceptability was evaluated by the patient during each care operation, by the investigating nursing team and by visiting nurses when care was provided outside the hospital (ease of dressing use [application/removal], dressing conformability, painless/painful removal, odour).
Statistical analysis
The descriptive statistical analysis was performed on an intention-to-treat basis for both the principal and secondary endpoints and considered all the patients included in the trial. *Total different from 43 because several replies were possible the outpatient nature of the trial. The trial population at inclusion was characterized by the parameters presented in Table 1 . With the majority of patients being women, nearly half the trial population had a history of cardiovascular disease (48.8%) and hypertension (37.2 %), associated with a range of disorders related to the age of this population (e.g. diabetes, allergies, arthritis, dyslipidemia, Parkinson's disease, alcoholic neuropathy, prostate adenoma). Numerous parameters describing the studied ulcers were documented at inclusion and are presented in Table 2 .
Results

Patients/study pathology
With a mean surface area of 10.71 cm 2 , the ulcers had been present for an average of 7.6 months and were recurrent in more than 60% of cases. At inclusion, only 7% of the ulcers showed healthy peri-lesional skin: 63% of these lesions were surrounded by pigmented dermatitis and/or white atrophy, both being the expression of a long-standing venous disorder. In addition, at inclusion the ulcers were painful (moderate to marked pain) in 37% of the cases.
Principal endpoint
The investigating physician documented the planimetric evaluation (tracing) at inclusion and then on a weekly basis. This showed that mean surface area, which at inclusion was 10.71 ±7.31 cm 2 , fell to 7.67 ±9.27 cm 2 after 6 weeks of treatment. Surface area reductions, given into percentage values, are shown in Table 3 .
The surface area of treated ulcers was reduced by a mean of 37.9 % after 6 weeks of treatment, and two patients' leg ulcers were healed before week 6. Figure 1 shows the percentage reduction in wound surface area over time.
After completing the 6 weeks of treatment, the investigating physicians considered that the wound was clinically improved in 73% of cases. Compression was combined with the trial dressing in 87% of the patients; among them, single layer was used for 86% of them and 14% of the patients had a multilayer compression therapy. The efficacy is illustrated by Figures 2-7 .
Secondary endpoints
Tolerance of the trial dressing: The investigating physician documented the local tolerance of the treatment on a weekly basis throughout the 6 weeks of follow-up. A total of 11 local adverse events were reported: their occurrence led to only one definitive treatment discontinuation; no temporary withdrawal was reported. Four of these local adverse events, which were of the same nature and occurred in the same centre, were deemed to be treatment-related, although they did not require treatment discontinuation. The events mainly concerned erosion (in patients who presented with damaged peri-lesional skin at inclusion) and eczema lesions which disappeared when a corticosteroid-based ointment was applied to the perilesional area. The surrounding skin condition under study was also documented throughout patient follow-up.
After 6 weeks of treatment with the trial dressing, 34% of the ulcers were surrounded by healthy skin compared with 7% at inclusion. Acceptability of the trial dressing: This clinical trial cumulated 1633 days of treatment and 521 local care operations were documented. Mean Urgocell NA application duration was 3.21±1.83 days. This dressing change frequency was less than 3 days when the leg ulcer was highly exudative and sometimes exceeded 7 days at the granulation or epithelialization phases or under a multilayer compression therapy. Acceptability was evaluated by the nursing staff each time the dressing was changed, and this occurred throughout the entire duration of the trial. Acceptability results are presented in Table 4 and show that the trial dressing was well accepted by both patients and nursing staff.
Discussion
The objective of this clinical trial was to evaluate the efficacy and the acceptability of the Urgocell NA dressing in the treatment of venous leg ulcers or mixed leg ulcers predominantly of venous origin. Forty-three patients were included in 15 active centres. Each patient, treated for at most 6 weeks, was the subject of a weekly physical, planimetric and photographic evaluation by the investigating physician. In addition, the nursing staff present in the investigating department, or the visiting nurse in charge of the care at home, documented each care operation conducted between two consecutive weekly evaluations.
The non-controlled nature of this study makes the results more difficult to interpret. However, considering the type of wound treated in this trial (in a debridement phase, with healthy surrounding skin present in only 7% of cases), the investigators deemed the efficacy to be satisfactory.
The mean surface area reduction observed (37.9%) after 6 weeks of treatment in this clinical trial is comparable with literature data for studies conducted on ulcers of the same aetiology and with similar surface areas and durations at inclusion. For example, Vin et al (2002) reported that in a clinical trial comparing Promogran and Adaptic dressings applied for 6 weeks to treat ulcers of the same aetiology and of a similar size (7.0 cm 2 and 9.5 cm 2 ), wound surface area was reduced by about 45% in the Promogran group and less than 30% in the Adaptic group (54.4% and 36.5% after 12 weeks of treatment with the Promogran and control group respectively). Hansson (1998) reported ulcer surface area reductions of 62%, 41% and 24% after 12 weeks of treatment with a dressing based on cadexomer iodine, a hydrocolloid dressing and a paraffin gauze dressing, respectively (mean ulcer surface areas of 8.8 cm 2 , 10.7 cm 2 and 7.1 cm 2 at inclusion).
Also, Thomas et al (1997) conducted a clinical trial to compare the Tielle and Granuflex dressings and observed a surface area reduction of about 45% and 35% respectively after 6 weeks of treatment. However, these ulcers were smaller at inclusion than those encountered in the Urgocell NA trial (4.31 cm 2 and 3.35 cm 2 respectively).
It was clearly reported in the literature by Margolis et al (2000) and Philips et al (2000) that leg ulcer healing rate correlates very strongly with two parameters -lesion size and duration -since ulcers heal more rapidly if they are initially less than 5 cm 2 in size and have been present for less than 6 months. The elevated absorption capacity of the Urgocell NA dressing meant that it only needed to be changed on average every 3.21 days.
Results reported in the literature (Dmochoska et al, 1999) foam dressings can be changed more frequently (every 2.46 and 2.39 days respectively on exudative ulcers). The same was also observed when considering hydrocolloid and hydrocellular dressings (2.7 and 2.8 days respectively) (Thomas et al, 1997) . Additionally, Andersen et al (2002) reported dressing change frequencies of 2.1 and 3.3 days for two polyurethane foam dressings compared in a clinical trial.
It should be noted that 14% of the patients were treated with a multilayer compression therapy. The dressing in this patient subgroup was left in place for 7.9 ±2.0 days without any evidence of adverse event occurrence. This dressing change frequency is comparable with that described by Smith et al (2004) (6.7±2.3 days) in a similar trial evaluating the Urgotul dressing combined with a K-Four multilayer compression.
In the clinical trial described here, the Urgocell NA dressing preserved (and in some cases improved) the condition of perilesional skin which was healthy in nearly 35% of the ulcers at the end of the treatment. All the patients included were analysed for tolerance (11 local adverse events): only four adverse events considered to be 'certainly' related to the treatment occurred and that was in one of the investigating centres.
The incidence of local adverse events with this new dressing was similar to (or lower than) that reported in the literature for comparable clinical trials (Hansson, 1998; Andersen et al, 2002; Vin et al, 2002) . Finally, some rare and transient maceration effects were noted, probably as a result of the highly exudative nature of the treated ulcers. Such effects are also widespread with other types of dressings, and on occasion may require treatment discontinuation (Andersen et al, 2002) .
Nursing staff evaluated the acceptability of the Urgocell NA dressing each time it was changed, and noted that it was very easy to use (dressing application and removal) and the patients particularly appreciated its pain-free removal.
The analysis of the clinical results in this French, multicentre clinical trial show that the Urgocell NA dressing is effective, safe and well accepted in the treatment of venous leg ulcers and mixed leg ulcers predominantly of venous origin, when used in association with a compression therapy. 
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■ A prospective, multicentre, non-comparative, phase III trial was undertaken to evaluate the efficacy and tolerance of Urgocell Non-Adhesive wound dressing, in the local management of venous leg ulcers.
■ A 6-week follow-up on a weekly basis showed, on 43 patients, a mean ulcer area reduction of 38%.
■ With a mean change frequency of 3.21 days, only four local adverse treatment-related events were noted.
■ A very good acceptability for the patient (painless removal) and for the nursing staff (ease of use), was recorded.
